## 6. Anti-infective medicines

### 6.2. Antibacterials

#### 6.2.1. Access group antibiotics

**Amoxicillin**

**INN**
Amoxicillin

**Medicine type**
Chemical agent

**Antibiotic groups**
ACCESS

**List type**
Core (EML) (EMLc)

**Indication**
Acute otitis media

**ICD11 code:** AB00

**ATC codes:**
J01CA04 EMLc

**EML status history**
First added in 2017 (TRS 1006)
Changed in 2023 (TRS 1049)

**Sex**
All

**Age**
Also recommended for children

**Therapeutic alternatives**
The recommendation is for this specific medicine

**Formulations**
- Oral > Liquid: 125 mg per 5 mL (as trihydrate) powder for oral liquid (EMLc); 250 mg per 5 mL (as trihydrate) powder for oral liquid (EMLc)
- Parenteral > General injections > unspecified: 250 mg in vial (as sodium) powder for injection; 500 mg in vial (as sodium) powder for injection; 1 g in vial (as sodium) powder for injection
- Oral > Solid > dispersible tablet: 250 mg (scored) (as trihydrate) (EMLc); 500 mg (scored) (as trihydrate) (EMLc)
- Oral > Solid > dosage form: 250 mg (as trihydrate); 500 mg (as trihydrate)

**Patent information**
Patents have expired in most jurisdictions

Read more about patents.

**Wikipedia**
Amoxicillin

**DrugBank**
Amoxicillin

---

**Expert Committee recommendation**

The Expert Committee recommended the inclusion of a new strength, child-friendly dispersible tablet formulation of amoxicillin + clavulanic acid (200 mg + 28.5 mg) as an Access group antibiotic on the core list of the EMLc for treatment of bacterial infections in children – specifically those infections for which amoxicillin + clavulanic acid is already recommended on the EMLc. The Committee noted that the 7:1 ratio of amoxicillin to clavulanic acid is associated with similar efficacy to the 4:1 ratio but has a reduced frequency of gastrointestinal adverse effects. The Committee endorsed the importance of age-appropriate formulations to better meet the dosing needs of children.

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended:
- the addition of new formulations of amoxicillin (dispersible, scored tablet, 250 mg and 500 mg) to the EMLc.
- the addition of a new formulation of amoxicillin + clavulanic acid (dispersible tablet 250 mg + 62.5 mg) to the EMLc.

---

**EML recommendations: Acute otitis media**

**First choice**
amoxicillin

**Second choice**
amoxicillin + clavulanic acid